La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Amylyx Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Amylyx Pharmaceuticals' Il CEO è Josh Cohen, nominato in Jan2013, e ha un mandato di 11.58 anni. la retribuzione annua totale è $ 7.42M, composta da 8.4% di stipendio e 91.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.14% delle azioni della società, per un valore di $ 6.21M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 3.6 anni.
Informazioni chiave
Josh Cohen
Amministratore delegato
US$7.4m
Compenso totale
| Percentuale dello stipendio del CEO | 8.4% |
| Mandato del CEO | 11.6yrs |
| Proprietà del CEO | 4.1% |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 3.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Compensazione vs Mercato: La retribuzione totale di Josh ($USD 7.42M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).
Compensazione vs guadagni: La retribuzione di Josh è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Josh Cohen (32 yo)
11.6yrs
Mandato
US$7,418,169
Compensazione
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.6yrs | US$7.42m | 4.14% $ 6.3m | |
| Co-Founder | 11.6yrs | US$7.42m | 4.03% $ 6.1m | |
| Chief Financial Officer | 3.6yrs | US$3.51m | 0.13% $ 199.0k | |
| Chief Legal Officer & General Counsel | 2.5yrs | US$3.01m | 0% $ 0 | |
| Chief Medical Officer | less than a year | US$2.37m | Nessun dato | |
| Chief Technical Operations Officer | no data | Nessun dato | Nessun dato | |
| Head of Investor Relations & Communications | no data | Nessun dato | Nessun dato | |
| Head of Global Marketing | 3.7yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
| Head of Canada & GM | 3.3yrs | Nessun dato | Nessun dato | |
| Head of Global Market Access | 3.7yrs | Nessun dato | Nessun dato | |
| Global Head of Regulatory Affairs | 4yrs | Nessun dato | Nessun dato |
3.6yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di AMLX è considerato esperto (durata media dell'incarico 3.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 10.6yrs | US$7.42m | 4.14% $ 6.3m | |
| Co-Founder | 10.6yrs | US$7.42m | 4.03% $ 6.1m | |
| Company Secretary & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Special Advisor & Member of Advisory Board | 3.6yrs | US$51.24k | Nessun dato | |
| Independent Chairman of the Board | 9.6yrs | US$385.07k | 1.03% $ 1.6m | |
| Chairman of The Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Board Observer & Advisor | 7.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 1.4yrs | US$681.15k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$348.59k | 0.0073% $ 11.1k | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 3.4yrs | US$342.12k | 0.0058% $ 8.8k |
3.6yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMLX sono considerati esperti (durata media dell'incarico 3.6 anni).